A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)
Frontiers in Pharmacology · 14.06.2023 · 14
DOI: 10.3389/fphar.2023.1159286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.06.2023. Verfasst von Cong-Cong Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Yantai Yuhuangding Hospital, Yantai, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The REFLECT phase-III trial has demonstrated the efficacy of lenvatinib in improving the overall survival of advanced hepatocellular carcinoma (HCC) patients, comparable to sorafenib. The rapidly evolving landscape of hepatocellular carcinoma therapy presents new avenues for lenvatinib. This study aims to provide a scientometric analysis of publications and predict research hotspots in this field.
Methods
Relevant publications were sourced from the Web of Science Core Collection (WoSCC) database up until November 2022. The bibliometrix tool in R was employed for scientometric analysis and visualization.
Results
A total of 879 publications from 2014 to 2022 were obtained from WoSCC that met the established criteria. These studies involved 4,675 researchers from 40 countries, with an average annual growth rate of 102.5%. The highest number of publications was from Japan, followed by China, Italy, and the United States. The largest proportion of studies, 14.0% ( n = 123), was contributed by FUDAN UNIV. The studies were published in 274 journals, with CANCERS ( n = 53) being the top journal, followed by FRONTIERS IN ONCOLOGY ( n = 51) and HEPATOLOGY RESEARCH ( n = 36). The top ten journals accounted for 31.5% of the 879 studies. The most prolific authors were Kudo M ( n = 51), Hiraoka A ( n = 43), and Tsuji K ( n = 38). A total of 1,333 keywords were analyzed, with the present research hotspots being “immune checkpoint inhibitors,” “prognosis,” and “pd-1.” Co-occurrence clustering analysis revealed the top keywords, authors, publications, and journals. Strong collaboration was identified in the field.
Conclusion
This scientometric and visual analysis provides a comprehensive summary of the published articles on lenvatinib in HCC during 2014–2022, highlighting the research hotspots, knowledge domain, and frontiers. The results can provide insights into future research directions in this field.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Yantai Yuhuangding Hospital, Yantai, China.
- School of Medicine, Huanghuai University, Zhumadian, Henan, China.
- Department of Respiratory Oncology, Fushan District People's Hospital, Yantai, China.
Zitieren
APA
Wang, C. C., Yu, C. Y., Zhang, J., Wang, R., & Kong, X. S. (2023). A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022). Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1159286
Vancouver
Wang CC, Yu CY, Zhang J, Wang R, Kong XS. A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022). Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1159286
BibTeX
@article{Wang2023,
author = {Wang, Cong-Cong and Yu, Cai-Yan and Zhang, Jing and Wang, Rui and Kong, Xiang-Shuo},
title = {A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1159286}
}
EUVIMED